Iptacopan (Fabhalta): Oral Factor B Drug for IgAN/PNH/C3G
Novartis' Iptacopan (Fabhalta), an oral Factor B inhibitor. APPLAUSE-IgAN: eGFR slope +49%. FDA approvals: PNH (2023), IgAN (2024 accelerated), C3G (2025).
Introduction: The First Oral Alternative-Pathway Complement Drug
IgA nephropathy (IgAN), paroxysmal nocturnal hemoglobinuria (PNH), and C3 glomerulopathy (C3G) are clinically distinct but share a common molecular driver: alternative pathway (AP) complement hyperactivation. Anti-C5 antibodies (eculizumab/ravulizumab) block downstream complement partially, yet upstream C3 deposition and tissue injury progress. Novartis' Iptacopan (LNP023 / Fabhalta), an oral selective Factor B inhibitor, is the first oral AP-specific drug approved across all three indications[1][2]. This article covers the MoA, key trials, and competitive positioning based on public sources.
1. Compound Profile
| Item | Detail |
|---|---|
| Generic name | Iptacopan |
| Brand name | Fabhalta |
| Development code | LNP023 |
| Sponsor | Novartis |
| Modality | Oral small-molecule, selective Factor B inhibitor (AP-specific) |
| Dose | 200 mg PO BID |
| Indications | PNH (FDA Dec 2023), IgAN (FDA Aug 2024, accelerated), C3G (FDA Mar 2025) |
| EMA | PNH approved May 2024 |
| Prophylaxis | Meningococcal / pneumococcal / Hib vaccination required |
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. Alternative Pathway Biology
C3b binds Factor B; Factor D cleaves the complex to form C3bBb (AP C3 convertase), amplifying C3/C5 cleavage and membrane-attack complex (MAC) formation. In IgAN, mesangial IgA immune complexes drive AP activation, leading to C3 deposition, proteinuria, and eGFR decline.
Differentiation vs other complement targets
- Anti-C5 (eculizumab/ravulizumab): downstream only; upstream C3 activation persists
- C3 inhibitor (pegcetacoplan): whole-pathway suppression but breakthrough hemolysis
- Anti-MASP2 (narsoplimab): lectin pathway focus
- Iptacopan: AP-selective; classical and lectin pathways preserved, including serum meningococcal bactericidal activity
3. Mechanism
Iptacopan binds Factor B's catalytic site with high affinity (IC50 ≈ 0.01 μM), blocking Bb fragment generation and C3 convertase assembly. Oral dosing rapidly suppresses plasma Factor B activity, disrupting the AP amplification loop and reducing C3 deposition, C3a/C5a anaphylatoxins, and MAC formation.
4. Clinical Evidence
4-1. APPLAUSE-IgAN Phase 3 (NCT04578834)[1]
| Item | Detail |
|---|---|
| Design | Randomized double-blind placebo-controlled, IgAN with UPCR ≥1.0 g/g |
| Interim (9 mo) | UPCR −38.3% vs placebo (95% CI 26.0–48.6%, p<0.0001) |
| Final (24 mo) | Annual eGFR slope −3.10 vs −6.12 mL/min/1.73m²/yr, 49.3% improvement (p<0.001) |
| Renal composite | HR 0.57 (p=0.003), N Engl J Med 2026 |
| Safety | Serious infections 6.7% vs 2.1% (managed with vaccination) |
FDA accelerated approval (Aug 2024) used interim UPCR; final analysis confirmed eGFR slope benefit.
4-2. PNH Phase 3: APPLY-PNH / APPOINT-PNH[3]
- APPLY-PNH (switch from anti-C5): 24-week Hb ≥2 g/dL increase rate 82.3% (iptacopan monotherapy), ≥12 g/dL rate 68.8% vs 1.8% (anti-C5)
- APPOINT-PNH (treatment-naïve): 97% with Hb ≥2 g/dL, 79% reaching ≥12 g/dL transfusion-free
- Peffault de Latour R, et al., N Engl J Med 2024
4-3. APPEAR-C3G Phase 3
- 6-month UPCR −35.1% (p=0.0014); 12-month composite 43.5% vs 25.0%
- FDA approval Mar 2025
5. Regulatory Timeline
| Date | Agency | Indication |
|---|---|---|
| 2023-12 | FDA | PNH |
| 2024-05 | EMA | PNH |
| 2024-08 | FDA | IgAN (accelerated) |
| 2025-03 | FDA | C3G |
6. Competitive Landscape (IgAN)
| Agent | MoA | FDA Status | Primary EP |
|---|---|---|---|
| Sparsentan | ETAR/AT1R dual | Full approval | UPCR −50% |
| Iptacopan | Factor B (AP) | Accelerated Aug 2024 | UPCR −38.3% + eGFR slope +49% |
| Sibeprenlimab | anti-APRIL | Accelerated Nov 2025 | UPCR −51.2% |
| Atrasentan | ETAR-selective | Approved Mar 2024 | UPCR −38.1% |
| Atacicept | BAFF/APRIL | Phase 3 (ORIGIN) | UPCR −46% |
| Zigakibart (BION-1301) | anti-APRIL | Phase 3 (BEYOND) | — |
Iptacopan is the only approved agent targeting complement directly in IgAN, with a non-overlapping MoA that positions it as a combination backbone with RAAS / ETAR / APRIL inhibitors.
7. Preclinical & Biomarkers
- IgAN models: ddY mice, passive Heymann nephritis — demonstrating C3 glomerular deposition blockade
- Complement biomarkers: Bb fragment, urinary sC5b-9, plasma C3a as direct AP activity readouts
- Predictive markers: combined with UPCR/eGFR slope for treatment-response stratification
8. Points to Watch
- EMA and PMDA IgAN approvals (limited public data currently)
- Long-term infection risk in post-marketing surveillance
- Combination trials with Sibeprenlimab / Sparsentan / Atrasentan — four-pillar strategies
- Expansion to APOL1 FSGS, aHUS, IC-MPGN
- Japan market trajectory post-PNH approval
References
1. Perkovic V, et al. Iptacopan for Primary IgA Nephropathy (APPLAUSE-IgAN) — final analysis. N Engl J Med. 2026. NEJM / ClinicalTrials.gov: NCT04578834
2. Novartis. FDA grants accelerated approval to Fabhalta (iptacopan) for primary IgA nephropathy. August 2024. Novartis
3. Peffault de Latour R, et al. Oral Monotherapy with Iptacopan in PNH (APPLY-PNH). N Engl J Med. 2024. PubMed 38477987
4. Bomback AS, et al. Iptacopan in Complement 3 Glomerulopathy (APPEAR-C3G). Lancet 2025. ScienceDirect
5. Schubart A, et al. Small-molecule factor B inhibitor for complement-mediated diseases. PNAS 2019;116:7926-7931. PubMed 30926668